GlaxoSmithKline management on the open offer for GSK Pharma

  • 3:20
  • Published On: December 16, 2013
Cinema View
Embed
David Redfern, chief strategy officer at GlaxoSmithKline speaks to NDTV about the Rs 6,400 crore open offer for GSK Pharma and the reasons behind the company's decision to up its stake in its India unit.

Related Videos

GSK Consumer offer very good; Ranbaxy Lipitor recall to hurt
November 26, 2012 5:42
Prefer CMC, Bajaj Corp GSK Pharma stocks: Experts
September 10, 2012 13:19
Buy ITC, Bajaj, Hero Motocorp, GSK consumer, Lupin, Sun: Prashasta Seth
May 10, 2012 15:57
Stock Picks: TTK Prestige, VST Industries, GSK Consumers, Yes Bank, Havells India
December 13, 2011 24:32
Ambit's picks: TTK Prestige, VST Inds, GSK Consumer
December 13, 2011 18:34
Vaccine segment sees double-digit growth: GSK
May 06, 2011 2:25
GlaxoSmithKline on FY11 outlook
May 19, 2010 5:21
Stock picks for May 18, 2010
May 17, 2010 24:25
Prabhudas Lilladher's top picks
May 10, 2010 2:58
GSK bets big on vaccines
November 02, 2009 2:22
DRL, GSK ink pact to develop generics
June 16, 2009 3:23
Our Offerings: NDTV
  • मध्य प्रदेश
  • राजस्थान
  • इंडिया
  • मराठी
  • 24X7
Choose Your Destination